U.S. flag

An official website of the United States government

NM_004341.5(CAD):c.2634del (p.Ala879fs) AND not provided

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 12, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003054407.3

Allele description [Variation Report for NM_004341.5(CAD):c.2634del (p.Ala879fs)]

NM_004341.5(CAD):c.2634del (p.Ala879fs)

Genes:
LOC126806171:BRD4-independent group 4 enhancer GRCh37_chr2:27454350-27455549 [Gene]
CAD:carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
2p23.3
Genomic location:
Preferred name:
NM_004341.5(CAD):c.2634del (p.Ala879fs)
HGVS:
  • NC_000002.12:g.27232213del
  • NG_046394.1:g.19824del
  • NG_082495.1:g.832del
  • NM_001306079.2:c.2445del
  • NM_004341.5:c.2634delMANE SELECT
  • NP_001293008.1:p.Ala816fs
  • NP_004332.2:p.Ala879fs
  • NC_000002.11:g.27455080del
  • NC_000002.11:g.27455081del
Protein change:
A816fs
Molecular consequence:
  • NM_001306079.2:c.2445del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_004341.5:c.2634del - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV003332803Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Pathogenic
(May 12, 2022) 		germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

CAD mutations and uridine-responsive epileptic encephalopathy.

Koch J, Mayr JA, Alhaddad B, Rauscher C, Bierau J, Kovacs-Nagy R, Coene KL, Bader I, Holzhacker M, Prokisch H, Venselaar H, Wevers RA, Distelmaier F, Polster T, Leiz S, Betzler C, Strom TM, Sperl W, Meitinger T, Wortmann SB, Haack TB.

Brain. 2017 Feb;140(2):279-286. doi: 10.1093/brain/aww300. Epub 2016 Dec 21.

PubMed [citation]
PMID:
28007989

A Patient With CAD Deficiency Responsive to Uridine and Literature Review.

Zhou L, Xu H, Wang T, Wu Y.

Front Neurol. 2020;11:64. doi: 10.3389/fneur.2020.00064.

PubMed [citation]
PMID:
32117025
PMCID:
PMC7012989
See all PubMed Citations (5)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003332803.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

This sequence change creates a premature translational stop signal (p.Ala879Glnfs*3) in the CAD gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CAD are known to be pathogenic (PMID: 28007989, 32117025, 32820246, 33497533). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CAD-related conditions. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024